Back to search

Article

Disrupted copper availability in sporadic ALS: Implications for Cu <sup>II</sup> (atsm) as a treatment option

2020-04-18

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objective</h4> The copper compound Cu II (atsm) is in phase 2/3 testing for treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Cu II (atsm) consistently and reproducibly ameliorates neurodegeneration in mutant SOD1 mouse models of ALS where its neuroprotective activity has been ascribed in part to improving availability of copper to essential cuproenzymes. How...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
aa91b24e-d79d-5b59-af35-97f32f328073
DOI
10.1101/2020.04.17.047704
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Disrupted copper availability in sporadic ALS: Implications for Cu <sup>II</sup> (atsm) as a treatment optionDOI 10.1101/2020.04.17.047704
Select a neighboring publication to make it the new centre.